,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04', 'enhertu']
exciting results announced at #asco22 from the destiny-breast04 trial confirm that the antibody-drug conjugate fam-trastuzumab deruxtecan (enhertu) can be used to treat certain patients with her2-low unresectable and/or metastatic breast cancer. 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ